Fig. 2

CircEAF2 is associated with EBV infection and clinical outcomes in DLBCL patients (N = 100). A Relative expression of circEAF2 according to tumor EBER-ISH, tumor EBV DNA or serum EBV DNA of DLBCL patients. Results on tumor samples was further transformed by LogE. B Correlations of circEAF2 expression with EBV DNA copy number in tumor and in serum. C Progression-free survival (PFS) and overall survival (OS) of DLBCL patients according to circEAF2 expression. D Forest plot showed univariate and multivariate prognostic analysis for PFS and OS of DLBCL patients. EBER, EBV-encoded RNA; ISH, in-situ hybridization; PFS, Progression-free survival; OS, overall survival; HR, Hazard ratio; CI, Confidence interval; LDH, Lactate dehydrogenase; IPI, International prognostic index; ECOG, Eastern Cooperative Oncology Group; CR, Complete remission; GCB, Germinal center B-cell